❓ Hon Sue Ellery questions the Minister for Health regarding a patient blood management program at Fremantle Hospital, focusing on participation, consent, and adverse outcomes. The Minister's response clarifies the program's nature and outcomes.
AnsweredQoN 717Legislative Council
QuestionView source ↗
FREMANTLE
HOSPITAL — PATIENT BLOOD MANAGEMENT
717. Hon SUE ELLERY to the
parliamentary secretary representing the Minister for Health:
I refer to WA Health's patient blood management at
Fremantle Hospital between 2009 and 2012.
(1) How many
adults and how many children participated in the pilot blood transfusion
reduction program?
(2) Did all
patients at Fremantle Hospital who participated in the pilot provide informed
written consent?
(3) Were all the patients who participated in the pilot
monitored for adverse outcomes?
(4) How many, if any, patients who participated in the pilot
experienced adverse outcomes?
HOSPITAL — PATIENT BLOOD MANAGEMENT
717. Hon SUE ELLERY to the
parliamentary secretary representing the Minister for Health:
I refer to WA Health's patient blood management at
Fremantle Hospital between 2009 and 2012.
(1) How many
adults and how many children participated in the pilot blood transfusion
reduction program?
(2) Did all
patients at Fremantle Hospital who participated in the pilot provide informed
written consent?
(3) Were all the patients who participated in the pilot
monitored for adverse outcomes?
(4) How many, if any, patients who participated in the pilot
experienced adverse outcomes?
AnswerView source ↗
I thank the honourable member for some notice of this
question.
(1) The
program was not specifically applied to children as the patient blood
management in paediatrics guidelines have yet to be published. It is not
possible to say how many adults participated. However, it can be said that the
Fremantle program started with the elective cardiac surgery population,
expanded into elective orthopaedic surgeries, and then became a general
standard of care for all patients. PBM is not a single event, recommendation or
application tool that can be counted. It is a re-education of diagnosing
anaemia and iron deficiency and how to treat appropriately, as well as reducing
the blood loss of any patient. Due to the manner in which this program was
staged through the specialties, there is no way to count how many patients were
in this category from 2009–2010 to present.
(2) The
Fremantle program was not a pilot program, a clinical trial or a research
study. It was about the embedding of national guidelines into routine clinical
practice. Consent should be obtained when patients receive blood products.
(3) Monitoring
for adverse events is routinely performed on in-patients regardless of whether
the patient received blood products. As the Fremantle program was not a pilot
program, clinical trial or a research study, no additional monitoring, beyond
usual care, was provided.
(4) No adverse
outcomes have been reported. Comparison of the transfused versus non-transfused
orthopaedic patients treated at Fremantle during this period shows that the
latter had shorter lengths of stay, reduced infection rates, reduced respiratory
complications and a lower number of re-admissions.
question.
(1) The
program was not specifically applied to children as the patient blood
management in paediatrics guidelines have yet to be published. It is not
possible to say how many adults participated. However, it can be said that the
Fremantle program started with the elective cardiac surgery population,
expanded into elective orthopaedic surgeries, and then became a general
standard of care for all patients. PBM is not a single event, recommendation or
application tool that can be counted. It is a re-education of diagnosing
anaemia and iron deficiency and how to treat appropriately, as well as reducing
the blood loss of any patient. Due to the manner in which this program was
staged through the specialties, there is no way to count how many patients were
in this category from 2009–2010 to present.
(2) The
Fremantle program was not a pilot program, a clinical trial or a research
study. It was about the embedding of national guidelines into routine clinical
practice. Consent should be obtained when patients receive blood products.
(3) Monitoring
for adverse events is routinely performed on in-patients regardless of whether
the patient received blood products. As the Fremantle program was not a pilot
program, clinical trial or a research study, no additional monitoring, beyond
usual care, was provided.
(4) No adverse
outcomes have been reported. Comparison of the transfused versus non-transfused
orthopaedic patients treated at Fremantle during this period shows that the
latter had shorter lengths of stay, reduced infection rates, reduced respiratory
complications and a lower number of re-admissions.
Explore WA Government Data
Search the full archive in the free dashboard, or query programmatically via API.
Explore more
Government Gazette
Appointments, regulatory notices, planning changes.
Hansard
Debates, questions, speeches and sentiment.
Tabled Papers
Reports and documents tabled in Parliament.
Committees
Committee profiles and recent reports.
Regulations
Subsidiary legislation with filters and summaries.
Bills
Proposed laws and parliamentary progress.
Acts
Current WA legislation and summaries.
Explanatory Memoranda
Bills with EMs (text/PDF) available.
Members
MP profiles, party breakdown and rankings.
Pollie Rankings
Data-driven rankings across 19 categories.
Amendment Chains
Track how schemes and regulations evolve over time.